A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - CA057-001
Updated: 24 May, 2023 | ClinicalTrials.gov
Print Friendly Summary
Inclusion Criteria: - Participant has documented diagnosis of MM and measurable disease, defined as any of the following: - M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or - M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP) - For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. - Participants received 1 to 3 prior lines of antimyeloma therapy. - Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy. Exclusion Criteria: - Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor. - For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity. - Participant has had prior treatment with CC-92480 or pomalidomide. Other protocol-defined criteria apply.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information